GalvusTreatment for Diabetes Type 2
Novartis announces three-month extension of US regulatory review for Galvus to assess recently available clinical data
Available Clinical Data Substantial new short- and long-term data being submitted to US Food and Drug Administration (FDA)
Novartis committed to working closely with the FDA to gain approval for Galvus, which has been studied in more than 7,000 people to date
BASEL, Switzerland, November 13, 2006 - Novartis announced today a three-month extension in the US regulatory review period for the oral anti-diabetes medicine Galvus (vildagliptin) until the end of February 2007 after deciding to submit recently available clinical data to the US Food and Drug Administration (FDA).
These additional data being submitted to the FDA add about 1,000 patient years of treatment experience with Galvus. These recently available data include results from short- and long-term studies for periods of up to two years, both as a monotherapy or in combination with other anti-diabetes medicines.
These new data further support the proposed dosing regimen and indications as well as complement the risk/benefit profile of Galvus. In particular, they provide further evidence confirming data submitted earlier to the FDA showing that skin findings identified in a single species during a preclinical animal study have not been seen in clinical studies with patients treated for type 2 diabetes.
"We are confident of the efficacy and safety of Galvus and in gaining US approval," said James Shannon, M.D., Head of Development at Novartis Pharma AG. "We believe this additional information being provided to the FDA will strengthen the already robust data supporting Galvus as a new and needed treatment option for patients with type 2 diabetes."
Novartis is committed to working closely with the FDA in its review of Galvus, which the agency accepted for review in March 2006 after Novartis made the filing in January 2006. The FDA has the option of extending the typical 10-month review period for new drugs if a company submits significant additional data during the last three months of the review. An extensive clinical trial program is ongoing for Galvus.
Posted: November 2006
- Novartis Committed to Making Galvus Available for Patients with Type 2 Diabetes After US Regulators Issue ''Approvable Letter'' - February 26, 2007
- New drug application for Galvus, an innovative oral therapy for people with type 2 diabetes, accepted for review by FDA - March 30, 2006